Drug intelligence / Profile preview

Fel-O-Vax Lv-K IV + CaliciVax

Development stage: Unknown
Lead developer: Boehringer Ingelheim Vetmedica
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

Fel-O-Vax Lv-K IV + CaliciVax is a multivalent veterinary vaccine administered subcutaneously to healthy cats 8 to 10 weeks of age or older. It is formulated as a killed virus and killed Chlamydia vaccine to aid in the prevention of diseases caused by Feline Leukemia Virus, Feline Rhinotracheitis Virus, Feline Calicivirus (including the hemorrhagic VS-FCV strain), Feline Panleukopenia Virus, and to reduce the severity of disease due to Chlamydia psittaci. The product has been associated with manufacturers such as Elanco, Boehringer Ingelheim Vetmedica, and Fort Dodge Animal Health through a series of acquisitions and rebranding efforts. [1, 9, 13, 15]

Brand names: Fel-O-Vax Lv-K IV + CaliciVaxTruFel HC2PCh-FeLVFel-O-Vax IV + CaliciVax
Other names: Fel-O-Vax Lv-K IV + CaliciVax-Elanco-Boehringer Ingelheim-Fort Dodge Animal Health-Feline leukemia virus-Feline rhinotracheitis virus-Feline calicivirus-Feline panleukopenia virus-Chlamydia psittaci-Vaccine-subcutaneous-Feline Leukemia-Feline Viral Rhinotracheitis-Feline Caliciviral Disease-Feline Panleukopenia-Feline ChlamydiosisFeline Leukemia-Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Vaccine

Targets

FCV (Feline calicivirus)FPV (Feline panleukopenia virus)FHV-1 (Feline herpesvirus 1)FeLV (Feline leukemia virus)

Beyond the preview

Go deeper on Fel-O-Vax Lv-K IV + CaliciVax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fel-O-Vax Lv-K IV + CaliciVax.

Explore the full profile